Back to Search Start Over

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Authors :
Emprou C
Le Van Quyen P
Jégu J
Prim N
Weingertner N
Guérin E
Pencreach E
Legrain M
Voegeli AC
Leduc C
Mennecier B
Falcoz PE
Olland A
Santelmo N
Quoix E
Massard G
Guenot D
Chenard MP
Beau-Faller M
Source :
Cancer medicine [Cancer Med] 2018 Jul; Vol. 7 (7), pp. 3278-3291. Date of Electronic Publication: 2018 May 29.
Publication Year :
2018

Abstract

Lymph node metastasis is an important prognosis factor in non-small cell lung cancer (NSCLC) patients. The aim of this study was to investigate the role of epithelial to mesenchymal transition (EMT) in lymph node progression in the early stages of NSCLC. We studied a retrospective cohort of 160 consecutive surgically treated NSCLC patients with available frozen tumor samples for expression of EMT markers (CDH1, CTNNB1, CDH2, and VIMENTIN), inducers (TGFB1, c-MET, and CAIX), and transcription factors (EMT-TF: SNAI1, SNAI2, ZEB1, TWIST1, and TWIST2). Partial EMT was more frequent in N1-2 (N+) vs N0 patients (P < .01). TGFB1 (P = .02) as well as SNAI2 (P < .01) and TWIST1 (P = .04) were the most differentially expressed genes in N+ tumors. In this group, ZEB1 was correlated with all EMT inducers and other EMT-TFs were overexpressed depending on the inducers. CAIX was an independent prognostic factor for overall survival (IC 95% HR: 1.10-5.14, P = .03). Partial EMT is involved in lymph node progression of NSCLC patients and depends on the TGFβ pathway. EMT-TFs are differentially expressed depending on EMT inducers. CAIX might be a relevant prognostic marker in early stage NSCLC.<br /> (© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
2045-7634
Volume :
7
Issue :
7
Database :
MEDLINE
Journal :
Cancer medicine
Publication Type :
Academic Journal
Accession number :
29845746
Full Text :
https://doi.org/10.1002/cam4.1545